OLDWICK, N.J., Sept. 5, 2019 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical
company dedicated to intercepting and preventing immune-mediated
diseases, today announced that management will present at the H.C.
Wainwright 21st Annual Global Investment Conference on
Tuesday, September 10, 2019, at
8:45 am E.T. The conference is being
held at the Lotte New York Palace, New York, NY.
The presentation will be webcast live and can be accessed by
visiting the Events and Webcasts section of the Company's
website: http://investors.proventionbio.com/events. A replay
of the webcast will be archived on the Company's website for 90
days following the presentation.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage
biopharmaceutical company leveraging a transformational drug
development strategy that is focused on the prevention or
interception of immune-mediated disease. Provention's mission
is to in-license, transform and develop therapeutic candidates
targeting the high morbidity, mortality and escalating costs of
autoimmune and inflammatory diseases including: type 1 diabetes
(T1D), Crohn's disease, celiac disease, and lupus. Provention's
diversified portfolio includes advanced-stage product development
candidates that have undergone clinical testing by other
companies.
Investors:
Sam Martin,
Argot Partners
sam@argotpartners.com
212-600-1902
Media:
David Rosen
david.rosen@argotpartners.com
212-600-1902
View original
content:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300912133.html
SOURCE Provention Bio, Inc.